{
  "guideline": {
    "id": "PA166328671",
    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Belzutifan - CYP2C19 and/or UGT2B17",
    "objCls": "PGx Association",
    "source": "FDA",
    "version": 0,
    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328671",
    "relatedChemicals": [
      {
        "id": "PA166268761",
        "name": "belzutifan",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      },
      {
        "id": "PA37189",
        "name": "UDP glucuronosyltransferase family 2 member B17",
        "symbol": "UGT2B17"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166309881",
      "name": "Recommendation Annotation PA166309881",
      "population": "Affected subgroup: CYP2C19 and/or UGT2B17 poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166268761",
          "name": "belzutifan",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452208380,
        "html": "<p>&quot;Results in higher systemic concentrations and may result in higher adverse reaction risk (anemia, hypoxia). Monitor patients who are poor metabolizers for both genes for adverse reactions.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166308261",
      "name": "Recommendation Annotation PA166308261",
      "population": "Affected subgroup: CYP2C19 and/or UGT2B17 poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166268761",
          "name": "belzutifan",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452193140,
        "html": "<p>&quot;Results in higher systemic concentrations and may result in higher adverse reaction risk (anemia, hypoxia). Monitor patients who are poor metabolizers for both genes for adverse reactions.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [],
  "version": "2024-03-08-14-34"
}